Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension

RADNOR, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. MLYS, a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that the…#radnor #launchhtnnct06153693 #joncongleton #mineralys #launchhtn #phase3 #advancehtn #transformhtn #ckd #pennsylvania
Source: Reuters: Health - Category: Consumer Health News Source Type: news